Amount Raised
$23 Million
Round Type
Series C
DallasOtherHealthcareHealth CareDescription
Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination therapies for orthopedic infections, announced today the completion of an oversubscribed $23 million Series C equity financing. The proceeds leave Osteal well-funded to submit its New Drug Application (NDA) submission to FDA and accelerate preparation for commercial launch of VT-X7, its lead therapy for the treatment of periprosthetic joint infection (PJI).
Who to call at Osteal Therapeutics, and when
A new round usually means Osteal Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Osteal Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Osteal Therapeutics, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Osteal Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Osteal Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.